- Open Access
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease
Journal of Hematology & Oncology volume 9, Article number: 53 (2016)
Previous studies have demonstrated that regulatory T cells (Tregs) play a protective role in the pathogenesis of chronic graft-versus-host disease (cGVHD). Tregs constitutively express the gene of the transcription factor Foxp3 whose CNS2 region is heavily methylated in conventional CD4+ T cells (CD4+Tconvs) but demethylated in Tregs.
Here, we assessed the impact of azacytidine (AZA) on cGVHD in a well-established murine model of sclerodermic cGVHD (B10.D2 (H-2d) → BALB/cJ (H-2d)).
The administration of AZA every 48 h from day +10 to day +30 at the dose of 0.5 mg/kg or 2 mg/kg mitigated chronic GVHD. Further, AZA-treated mice exhibited higher blood and thymic Treg frequencies on day +35, as well as higher demethylation levels of the Foxp3 enhancer and the IL-2 promoter in splenocytes at day +52. Interestingly, Tregs from AZA-treated mice expressed more frequently the activation marker CD103 on day +52. AZA-treated mice had also lower counts of CD4+Tconvs and CD8+ T cells from day +21 to day +35 after transplantation, as well as a lower proportion of CD4+Tconvs expressing the Ki67 antigen on day +21 demonstrating an anti-proliferating effect of the drug on T cells.
Our results indicate that AZA prevented sclerodermic cGVHD in a well-established murine model of cGVHD. These data might serve as the basis for a pilot study of AZA administration for cGVHD prevention in patients at high risk for cGVHD.
Despite its association with graft-versus-tumor effects [1–6], chronic graft-versus-host disease (cGVHD) remains an important limitation of allogeneic hematopoietic cell transplantation (allo-HCT) [7–9]. CGVHD manifestations can be remarkably polymorphic, ranging from isolated lichenoid cunatenous and/or oral mucosa lesions to dramatic multi-systemic disease mimicking severe forms of systemic lupus erythematosus or systemic sclerosis [8, 10].
Recent progresses have been made in our understanding of cGVHD pathogenesis [10, 11]. It is now well-demonstrated that clinical manifestations of cGVHD in humans are mediated by a complex immune reaction involving donor conventional CD4+ and CD8+ T cells, regulatory T cells (Tregs), B cells, and regulatory B cells [10, 12, 13]. However, the beneficial effect of in vitro [14, 15] or in vivo [6, 16–18] T-cell depletion of the graft at preventing cGVHD demonstrates a primary role for donor T cells in cGVHD pathogenesis.
Regulatory T cells (Tregs) represent a fraction of CD4+ T cells that is indispensable for maintaining immunological self-tolerance [19, 20]. Tregs constitutively express the forkhead box protein 3 factor (Foxp3) in their nuclei, and CD25 (the high-affinity component of the trimeric form of the interleukin 2 (IL-2) receptor) on their cell surface [19, 20]. Consequently, IL-2 is the key cytokine for Treg homeostasis [20, 21]. Interestingly, an altered Treg homeostasis has been observed in patients with cGVHD [22–25], while transfer of activated (CD103+) Tregs ameliorated cGVHD in a mouse-to-mouse model of cGVHD . Further, remarkably, correction of Treg homeostasis by administration of low-doses of IL-2 induced clinical responses in approximately 50 % of patients suffering from steroid-refractory cGVHD .
Although forced expression of Foxp3 in conventional CD4+ T cells (CD4+Tconvs) confers them a suppressive activity , Foxp3 expression per se is not sufficient for stably maintaining Treg phenotype and suppressive functions . Indeed, Treg-specific epigenetic changes (such as DNA hypomethylation) are also involved in controlling the expression of some Tregs function-associated molecules such as IL-2ra, CTLA4, or Foxp3 itself . Among these epigenetic changes, Foxp3 conserved noncoding sequence 2 (CNS2) is unmethylated in Tregs while heavily methylated in CD4+Tconvs, and greatly contributes to the stability of Foxp3 expression as well as Treg phenotype and functions . Further, the Foxp3 enhancer is also demethylated in Tregs while heavily methylated in CD4+Tconvs . Previous studies have demonstrated that hypomethylating agents (HMA) such as azacytidine (AZA) or decitabine (DAC) induce Foxp3 expression both in vitro and in vivo [30, 31] through the demethylation of Foxp3 CNS2 region  and Foxp3 enhancer .
Mice and drugs
Twelve- to 14-week-old B10.D2 (H-2d, Jackson Laboratories, Bar Harbor, USA) and BALB/cJ (H-2d, Jackson Laboratories) mice were used as donors and recipients, respectively. All mice were maintained in top-filtered cages in a standard animal facility and provided with sterilized food. Sterilized water, supplemented with 1 % Baytril (Bayer HealthCare, Diegem, Belgium), was given from day 0 to the end of the experiment. Water was changed every 2–3 days. All experimental procedures and protocols used in this investigation were reviewed and approved by the Institutional Animal Care and Use Ethics Committee of the University of Liège (Belgium), reference 1438. The “Guide for the Care and Use of Laboratory Animals”, prepared by the Institute of Laboratory Animal Resources, National Research Council, and published by the National Academy Press, was followed carefully as well as European and local legislation. 5-Azacytidine (AZA, Sigma-Aldrich, St. Louis, MO) or Decitabine (DAC, Dacogen, Janssen-Cilag, Zug, Switzerland), solubilized in PBS (Lonza, Verviers, Belgium), were injected s.c. every 48 h from D + 10 to D + 30 at the dose of 0.5 mg/kg or 2 mg/kg for AZA and 0.75 mg/kg for DAC. Control mice did not receive any injection.
Cell preparation for bone marrow transplantation
Spleen, femurs and tibias from B10.D2 (or from BALB/cJ in case of syngeneic transplantation) mice were collected in sterile RPMI + 10 % FBS + 1 % penicillin/streptomycin. After red blood cell lysis (RBC lysis buffer; eBioscience, SD, USA), suspensions were passed through a 70 μm nylon filter mesh and washed with PBS + 3 % FBS + 1 % P/S. Cells were then resuspended and mixed in PBS at a concentration of 70 × 106 spleen cells and 10 × 106 bone marrow cells/200 μL and injected intravenously in recipient mice.
Bone marrow transplantation and scl-cGVHD
BALB/cJ recipient mice were transplanted as previously described by Jaffee and Claman . Briefly, recipients BALB/cJ mice (H-2d) first received a total body irradiation of 7 Gy (137Cs source, GammaCell 40, Nordion, Ontario, Canada). Five to six hours later, recipients were injected with 200 μL of the above described cell suspension. The severity of sclerodermatous cGVHD (scl-cGVHD) was assessed with a clinical scoring system as described earlier . Briefly, ear-tagged animals were individually scored three times/week for five parameters: weight loss (grade 1, 10–20 %; grade 2, >20 %), posture (1, kyphosis only at rest; 2, severe kyphosis when the animal moves), activity (1, moderate activity impairment; 2, no move unless stimulated), skin (1, erythema or scaling tail; 2, open lesion on the body surface), and hair loss (1, > 1 cm2; 2, > 2 cm2). Clinical score was generated by summation of the five criteria scores (0–10/10). Animals reaching a score of 8/10 or a weight loss of >20 % of initial weight were sacrificed to avoid unnecessary pain according to our local ethic committee recommendations. Mice were observed every day for general health during the whole course of the experiments.
After 52 days, mice were sacrificed by anesthesia with 2 % Isoflurane (Forene®, Abbott Laboratories, Chicago, Illinois, USA) followed by cervical dislocation. Confirmation of death was done by monitoring absence of heart contraction or respiratory movements for 15 min. Splenocytes and bone marrow cells were collected in sterile RPMI + 10 % FBS + 1 % P/S. Lungs and skin were harvested in 10 % formaldehyde while blood and serum were collected in K2EDTA tubes and SST tubes, respectively (Becton Dickinson, Franklin Lakes, New Jersey, USA).
Skin, lungs and thymus biopsies and immunohistochemistry
On day +29 after transplantation (two first cohorts of mice) or at sacrifice (day +52, third cohort of mice) skin samples of 0.5 cm2 from the upper back were obtained and directly fixed in 10 % formaldehyde for 48 h, embedded in paraffin and sectioned at 4–5 μm. Similarly, lungs (third cohort at day +52) and thymus (fifth cohort on day +35) were collected at sacrifice and directly fixed in 10 % formaldehyde for 48 h, embedded in paraffin and sectioned at 4–5 μm. Skin and lung sections were then stained with Goldner’s trichrome using Masson-Goldner staining kit following the manufacturer’s instructions (Merck Millipore, Darmstadt, Germany). Pulmonary fibrosis was assessed using the Ashcroft’s scale . Thymic sections were stained with hematoxylin-eosin. For CD11b staining, paraffin-embedded sections were deparaffinized in xylene and rehydrated through a graded ethanol series. Antigen was retrieved with EDTA buffer combined with heating in a pressure cooker. Slides were peroxidase blocked with a commercial protein block serum-free solution (Dako, Glostrup, Danemark) for 10 min and were then incubated with the CD11b antibody (Abcam PLC, Cambridge, UK) during 1 h at room temperature and detected with the Envision system (Dako) for 30 min. Colorimetric detection was completed with diaminobenzidine (Dako) and slides were then counterstained with hematoxylin. Slides were then examined by a blinded examinator (JS) using a scoring system consisting in an absolute count of CD11b+ cells in three different hotspots, defined as areas in which CD11b staining is particularly high, for each slide. The total number of positive cells was then normalized to the number of CD11b+ cells per mm2. Histological slides were then scanned with a Hamamatsu Nanozoomer 2.0 HT (Hamamatsu Photonics, Geldern, Germany).
Blood counts and flow cytometry
Blood was collected immediately after tail vein bleeding in BD Microtainer K2EDTA Tube (BD Biosciences, SD, USA). Splenocytes were obtained by crushing the spleen in RPMI 1640 + 10 % FBS. Blood cell populations were counted with a cell-dyn 3700 analyzer (Abbott Laboratories, Chicago, Illinois, USA). Erythrocytes were depleted using RBC lysis buffer (eBioscience) according to manufacturer’s instructions. Cells were washed in PBS + 3 % FBS (Lonza) before processing for flow cytometry. The following antibodies were used: anti-mouse CD3-V500 (500A2, Becton-Dickinson, Bedford, MA), anti-mouse CD3-PE (500A2), anti-mouse CD4-eFluor450 (RM4-5), anti-mouse CD4-APC-Cy7 (RM4-5, SONY Biotechnology, Weybridge, UK), anti-mouse CD8-PE-Cy7 (53–6.7), anti-mouse CD8-APC-eFluor780 (53–6.7), anti-mouse CD229.1-FITC (30C7, BD), anti-mouse CD25-APC (PC61.5), anti-mouse CD25-PE-Cy7 (PC61, BD), anti-mouse CD25-PercP-Cy5.5 (PC61.5), anti-mouse CD103-BV510 (M290, BD), anti-mouse CD90.2 APC (53–2.1) (all eBioscience unless indicated otherwise). Cells (1.5–2 × 106 cells/sample) were incubated with surface antibodies for 20 min at 4 °C in the dark and washed twice with PBS + 3 % FBS. Intracellular staining for Foxp3 and Ki67 was performed by using the FoxP3 staining buffer set (eBioscience). For pSTAT5 staining, the PerFix EXPOSE reagent kit (Beckman Coulter, Fullerton, CA) was used following the manufacturer’s instruction as previously reported . The following antibodies were used: anti-mouse Foxp3-APC (FJK-16 s, eBioscience), anti-mouse Foxp3-PE (FJK-16 s, eBioscience), anti-human phophoSTAT5-APC (pY694, BD) and anti-human Ki67-FITC (35/Ki-67, BD). Data were acquired on a FACS Canto II flow cytometer (Becton Dickinson) and analyzed with the FlowJo software 10.0.7 (Tree Star Inc., Ashland, OR). Cell phenotypes were defined as CD3+CD8+ for cytotoxic CD8+ T cells, CD3+CD4+Foxp3- for CD4+Tconvs and CD3+CD4+Foxp3+ for Tregs. In the thymus, populations were described as follow: CD90.2+CD4-CD8- for double negative (DN), CD90.2+CD4+CD8+ for double positive (DP), CD90.2+CD4+CD8- for single CD4 positive, CD90.2+CD4-CD8+ for single CD8 positive, and CD90.2+CD4+CD8-Foxp3+ for Tregs. Absolute counts were calculated by multiplying the percentage of positive cells in the lymphoid gate by the absolute lymphocyte count measured by the cell-dyn 3700 analyzer, as previously reported .
For qPCR assays, Tregs and CD4+Tconvs were sorted from spleen of unmanipulated B10.D2 mice using FACS Aria III (Becton Dickinson).
Methylation-sensitive restriction enzyme and qPCR (MSRE-qPCR)
Methyl-sensitive PCR were used to analyze the methylation status of the CpG island of the Foxp3 enhancer and the IL-2 promoter, as previously described [29, 39, 40]. Genomic DNA was prepared using PureLinkTM Genomic DNA Mini Kit (Invitrogen, CA, USA) and quantified. One hundred and fifty nanograms of genomic DNA isolated from murine splenocytes was digested overnight at 37 °C with 10U of HpaII or MspI enzymes for Foxp3 enhancer and with 10U of PleI or MlyI enzymes for IL-2 promoter analyses. The CpG islands and β-act genes were PCR amplified using the following specific primers: Foxp3 enhancer CpG island, 5′-ATCCTCGCCATCGTCTTCCTCAT-3′ (forward) and 5′-CCTGTTCTGGCTTTCTCATTGGCT-3′ (reverse); IL-2 CpG island, 5′- CTGTTTCCATGCTGAAGGTC-3′(forward) and 5′-GGGTGATGCTCCAACTTCAT-3′ (reverse); β-act (GenBank accession no. U89400), 5′-TAGCACCATGAAGATCAAG-3′ (forward) and 5′-CCTGCTTGCTGATCCACAT-3′ (reverse). Specific primers designed on CpG islands were selected according to the CpG island methylation tool server (http://urogene.org/methprimer). Quantitative real-time PCR was performed using the LightCycler 480 thermocycler and the KAPA SYBR FAST qPCR kit, following the manufacturer’s instructions (Kapa Biosystems, Wilmington, USA,), subsequently the melting curve analysis was performed. Data were normalized using the β-act Endogenous Control and β-act specific primer for uncut region by HpaII, MspI, PleI and MlyI. Differences between males and females were taken into account for Foxp3 analyses, since this gene gene is located on the X chromosome.
TCR Vβ CDR3-size spectratype analysis
The TCR Vβ CDR3-size spectratyping was performed as previously reported  (see supplemental data for more details).
The Mann-Whitney U test was used to compare data between experimental groups. Results are expressed as mean with SEM (for scl-GVHD scores), or median, 25th and 75th percentiles of the distribution (boxes), and whiskers extending to the 5th and 95th percentiles. The analysis of quantitative real time PCR data was based on 2−ΔΔCT values. Two-tailed P values <0.05 were considered as statistically significant. Statistical analyses were performed with the GraphPad Prism 5.0 software.
AZA mitigates scl-cGVHD
In a first set of two consecutive experiments, Balb/cJ mice were injected i.v. with 10.106 bone marrow cells and 70.106 splenocytes from B10.D2 donor mice after lethal irradiation. Mice were then given (or not) azacytidine (AZA) administered subcutaneously every 48 h from day +10 to day +30. We observed that AZA, at either 0.5 or 2 mg/kg doses, significantly mitigated cGVHD with mice from the AZA group having significantly lower cGVHD scores than control mice from day +35 to the end of the experiment (day +52) (Fig. 1a). In accordance with the similar cGVHD scores between the two groups of mice on day +29 after transplantation, skin fibrosis (assessed by trichrome staining) was similar in AZA and control mice at that time point (data not shown).
In a third experiment, we confirmed that AZA given at 2 mg/kg decreased cGVHD (Fig. 1b) and observed that decitabine (DAC, 0.75 mg/kg, n = 5) also mitigated cGVHD (Additional File 1: figure S1). We further evaluated skin fibrosis in the mice at the end of the experiment. As shown in Fig. 2, AZA-treated mice had higher total thickness (from epidermis to sub-cutaneous muscle layer)/collagen thickness (TT/CT) ratios, highlighting less skin fibrosis (Fig. 2a, b), but similar (and mild) lung fibrosis (Fig. 2c, d) than control mice on day 52 after transplantation. Interestingly, infiltration by monocytes/macrophages was similar in AZA and control mice on that day (Fig. 2e, f).
In a fourth experiment, we investigated whether AZA administered every 4 days from days 10 to 30 also prevented cGVHD. As shown in Additional File 1: figure S1, this was not the case, with AZA and control mice exhibiting similar cGVHD scores throughout the experiment.
Impact of AZA on blood cell counts and immune recovery
We next assessed the impact of AZA on blood cell counts and immune recovery in the first two experiments. We observed that AZA significantly decreased total white blood cell (Fig. 3a) and lymphocyte (Fig. 3b) counts on days +21 and +35 after transplantation, while hemoglobin levels remained comparable in both groups (Fig. 3c). Further, AZA significantly decreased absolute counts of both CD4+Tconvs (Fig. 3d) and CD8+ T cells (Fig. 3e) from day +21 to day +35 after transplantation. In contrast, there was a trend for higher absolute lymphocyte counts in AZA-treated mice on day +52. This was due to significantly higher numbers of CD3- lymphocytes (probably mainly B cells) in AZA-treated mice (P = 0.01), as observed previously by Choi et al. in a mouse-to-mouse model of acute GVHD . This is probably an indirect phenomenon (better B lymphopoiesis due to less intense cGVHD in AZA-treated mice) since this was not observed in mice given syngeneic transplantation (Additional File 1: figure S2).
Interestingly, the proportion of proliferative CD4+Tconvs and CD8+ T cells (as assessed by Ki67 expression) was lower in AZA-treated mice on day +21 after transplantation (Fig. 3f, g) (this effect was dose dependent since it was only observed in mice given 2 mg/kg of AZA), suggesting an anti-proliferating effect of AZA on T cells. However, upon AZA discontinuation, CD4+Tconvs and CD8+ T cells proliferation was restored and higher numbers of Ki67+ cells were observed in AZA treated mice at days +35 and +49 post-transplant. Comparable qualitative observations were made on day 35 with DAC in the third experiment (Additional File 1: figure S3).
AZA increases Treg frequency and induces demethylation of Foxp3 enhancer
Given that AZA induces Tregs in vitro, we assessed the impact of HMA on Treg reconstitution. In the two first experiments, we observed that AZA increased the frequency of Tregs (Fig. 4a) and decreased the CD4+Tconv/Treg ratio (P = 0.046 for mice treated with AZA 0.5 mg/Kg and P = 0.029 for mice treated with AZA 2 mg/kg) on day +35 after transplantation. In contrast, absolute counts of Tregs were significantly lower in AZA-treated mice on days +21 and +35 after transplantation (data not shown). Comparable findings were observed in the third experiment with AZA 2 mg/kg (Fig. 4b) and DAC (Additional File 1: figure S3). Further, interestingly, Tregs from the spleens of AZA- and DAC-treated mice expressed more frequently the activation marker CD103 than those from control mice on day +52 after transplantation, suggesting higher efficacy (Fig. 4c and Additional File 1: figure S3). A similar impact of AZA on Tregs was observed in mice given syngeneic grafts (Additional File 1: figure S4), demonstrating that the impact of AZA on Treg reconstitution was independent of cGVHD.
Previous studies have reported that CD8+Foxp3+ regulatory T cells expanded after experimental allogeneic bone marrow transplantation in mice and mitigated experimental acute GVHD [41, 42]. This led us to look whether AZA promoted the generation of CD8+Foxp3+ regulatory T cells in vivo. However, we failed to observe significant numbers of CD8+Foxp3+ regulatory T cells in control and in AZA-treated mice after either allogeneic or syngeneic transplantation (Additional File 1: figure S5).
The higher frequency of Tregs in AZA-treated mice on day +35 prompted us to assess the impact of AZA on the methylation status of the Foxp3 enhancer. We first quantified the methylation status of Foxp3 enhancer in CD4+ Tconvs and Tregs isolated from the spleen of healthy mice. For this, DNA was extracted and digested with two restriction enzymes, Hpall and Mspl, both recognizing CG sequences. It is worth to note, however, that Hpall is not able to cut methylated sequences. As expected, no differences were observed between groups after Mspl digestion, while Hpall digestion demonstrated reduced methylation levels of the Foxp3 enhancer in Tregs in comparison with CD4+Tconvs, in agreement with studies previously published by others [29, 39] (Fig. 4d). We then assessed the methylation status of the Foxp3 enhancer in total spleen cells collected in cGVHD mice at the end of the experiment (on day +52 after transplantation). As hypothesized, we observed significantly less methylation of the Foxp3 enhancer in AZA-treated mice (Fig. 4e). Similar findings were made in DAC-treated mice (Additional File 1: figure S3).
Since the mTOR pathway is constitutively inactivated in Tregs, they rely mainly on the STAT5 pathway for IL-2 signaling [37, 43]. In order to further investigate the impact of AZA on day 30 after transplantation, we studied a fifth cohort of mice given or not AZA 0.5 or 2 mg/kg every other day from day +10 to day +30. In that cohort, mice were sacrificed on day +30 after transplantation. We observed that Tregs recovered from the spleen of mice treated with AZA 2 mg/kg had higher levels of phosphorylated STAT5 (pSTAT5) than Tregs from control mice (Fig. 4f). Further, they had also higher Tregs versus Tconvs ratio of STAT5 phosphorylation level than control animals (Fig. 4g). This higher IL-2 signaling in Tregs from AZA-treated mice than in those from control mice prompted us to assess the methylation status of the IL-2 promoter in spleen cells from control and AZA-treated mice on day +52 after transplantation. For this, DNA was digested with 2 restriction enzymes, PleI and MlyI. Both enzymes recognize same CG sequences but PleI is sensitive to methylation and is not able to cut when these sequences are methylated. No differences were observed between groups after MlyI treatment used as control while PleI digestion demonstrated reduced methylation levels in AZA-treated compared to control mice (Fig. 4h), in agreement with findings previously published by other groups [44–46].
AZA increases Treg frequency in thymus on day +35
Given that the thymus is the site of natural Treg generation on the one hand, and that thymic defects have been involved in the pathogenesis of cGVHD on the other hand [47, 48], we compared the thymus of AZA-treated and control mice on day +35 after transplantation in a last experiment. We observed that AZA-treated mice had less cellularity, higher percentages of double negative thymocytes, and a trend for lower percentages of double positive lymphocytes (Fig. 5a). Interestingly, there was a significantly higher proportion of Tregs (defined as CD90.2+CD4+CD8-Foxp3+) in the thymus of AZA-treated mice than in those from control mice (Fig. 5b and c). However, the proportion of Foxp3 double positive thymocytes was very low and similar in both groups of mice (data not shown), suggesting that the higher Treg frequency observed in the thymus of AZA-treated mice was due to higher Treg thymic recirculation. Finally, although adequate cortico-medullar differentiation was conserved in both control and AZA-treated mice, thymus from AZA-treated mice tended to have smaller sizes (Fig. 5d), in agreement with their lower cellularity (Fig. 5c).
AZA does not restrict T-cell receptor Vβ (TCRVβ) repertoire
Given the anti-proliferative impact of AZA on T cells, we compared the diversity of the TCRVβ repertoire on days +35 and +52 after transplantation. As shown in Additional File 1: figure S6, AZA did not significantly impact TCRVβ repertoire diversity.
Previous studies have demonstrated that HMA induced the generation of Tregs in vitro, and prevented acute GVHD in mouse-to-mouse models of transplantation [30, 31]. Given the important divergences in the pathogenesis of acute and chronic GVHD, we sought to investigate the impact of AZA in a well-established CD4-dependent murine model of scl-cGVHD. We selected the dose and schedule of AZA administration based on previous publications in mouse-to-mouse models of acute GVHD [30, 31], and on prior observations by our group in a humanized mouse model of GVHD . The dose of 2 mg/kg is close to the dose used in patients with acute myeloid leukemia (75 mg/m2) [50, 51]. Several observations were made.
First and most importantly, AZA indeed mitigated cGVHD. This achievement was dependent on the schedule of AZA administration since injection of AZA 2 mg/kg every 2 days but not every 4 days was able to decrease cGVHD severity. The ability of AZA to prevent cGVHD in our mouse model is in line with the low incidence of cGVHD observed in patients receiving donor lymphocytes infusion and AZA as treatment of acute myeloid leukemia relapse after allo-HCT , and consistent with the very low incidence of extensive cGVHD observed in patients given prophylactic AZA after allo-HCT [53, 54], although the latter patients also received alemtuzumab in the conditioning regimen (which is associated with a very low incidence of cGVHD by itself ).
At least two mechanisms were involved in cGVHD prevention by AZA. First, AZA had an antiproliferative effect on Tconvs during treatment. This is in line with previous reports that demonstrated an anti T-cell proliferative impact of HMA in vitro [30, 31]. Secondly, mice given AZA had significantly higher Treg frequencies on day 35 after transplantation, while a higher frequency of Tregs had an activated (CD103+) phenotype on day +52 after transplantation. These observations are particularly relevant given that a prior study had observed that in vivo-activated CD103+ donor Tregs were much more efficient than resting donor Tregs at ameliorating ongoing cGVHD . These results are in concordance with the higher Treg levels observed in patients given prophylactic AZA after allo-HCT .
Interestingly, we also observed a higher frequency of Tregs in the thymus of AZA-treated mice on day +35 after transplantation. Whether this was due to a higher neogeneration of Tregs by the thymus or to a higher frequency of peripheral Tregs recirculating into the thymus remains to be determined in further experiment using Rag2pGFP mice . Indeed, we did not observe any increase in the proportion of double positive thymocytes expressing Foxp3 in the thymus of AZA-treated mice compared to those of control animals.
It is likely that the higher Treg frequency observed in AZA-treated mice on day +35 is the result of demethylation of several genes. This assumption is supported by the demonstration of lower methylation status of both the Foxp3 enhancer and the IL-2 promoter in the spleens from AZA-treated mice in our study. Demethylation of the IL-2 promoter is particularly relevant, given the primordial role of IL-2 in Treg homeostasis . In line with the demethylation status of the IL-2 promoter in AZA-treated mice, we observed higher pSTAT5 levels in Tregs from AZA-treated than from control mice on day +30 after transplantation, confirming that IL-2 signaling in Tregs was higher in AZA-treated than in control mice.
Finally, as expected, AZA decreased blood counts and delayed immune recovery. However, this negative impact of the drug was rapidly corrected after AZA discontinuation. Further, interestingly, AZA did not significantly reduce the diversity of the TCRVβ repertoire.
In summary, our results indicate that AZA prevented scl-cGVHD in a well-established murine model of cGVHD. This was correlated with the demonstration of anti-proliferative effects of AZA on T cells, as well as with a higher frequency of Tregs (and particularly of activated CD103+ Tregs) in mice receiving AZA. These observations might serve as basis for pilot studies of AZA administration for cGVHD prevention in patients at high risks for cGVHD or for treatment of steroid-refractory scl-cGVHD.
allo-HCT, allogeneic hematopoietic cell transplantation; AZA, azacytidine; cGVHD, chronic graft-versus-host disease; DAC, decitabine; Foxp3, forkhead box protein 3 factor; HMA, hypomethylating agents; Scl-cGVHD, sclerodermatous cGVHD; Tconvs, conventional CD4+ T cells; TCRVβ, T-cell receptor Vβ; Tregs, regulatory T cells
Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462–8.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant T: Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–33.
Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers MED, Mielcarek M, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003.
Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socie G. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24:1852–8.
Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P, Li QC, Zhang ZM, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59.
Baron F, Zachee P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol. 2015;8:4.
Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socie G. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–9.
Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM, Colado E, Martin J, Vazquez L, del Canizo C, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14:1163–71.
Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, Bacigalupo A, Rambaldi A, Bonifazi F, Bosi A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8:107.
Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374–84.
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443–58.
de Masson A, Bouaziz JD, Le Buanec H, Robin M, O’Meara A, Parquet N, Rybojad M, Hau E, Monfort JB, Branchtein M, et al. CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015;125:1830–9.
Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120:1479–93.
Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012;30:3194–201.
Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J, de la Rubia J, Bargay J, Caballero D, Diez-Martin JL, et al. Allogeneic transplantation of CD34 + -selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant. 2001;28:349–54.
Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375–82.
Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–7.
Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.
Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64.
Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14:154–65.
Humblet-Baron S, Franckaert D, Dooley J, Bornschein S, Cauwe B, Schonefeldt S, Bossuyt X, Matthys P, Baron F, Wouters C, Liston A. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016. doi:10.1016/j.jaci.2015.12.1314. [Epub ahead of print].
Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011;118:5021–30.
Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra143.
Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, Strober S, Zeng D. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107:2993–3001.
Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Gregoire M, Gaugler B, Mohty M. Increased Th17/Treg ratio in chronic liver GVHD. Bone Marrow Transplant. 2014;49:539–44.
Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. In vivo-activated CD103 + CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008;112:2129–38.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.
Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38:414–23.
Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009;182:259–73.
Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, Garcia JL, Carrancio S, Hernandez-Campo P, Gonzalez FJ, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115:107–21.
Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129–39.
Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol. 1983;77:1–12.
Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14:365–78.
Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011;4:318–33.
Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R, Drion P, Zilberberg J, Bogen B, et al. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS One. 2014;9:e113764.
Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467–70.
Ehx G, Hannon M, Beguin Y, Humblet-Baron S, Baron F. Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget. 2015;6:43255–66.
Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, de Bock M, et al. Immune recovery after allogeneic hematopoietic stem cell transplantation following Flu-TBI versus TLI-ATG conditioning. Clin Cancer Res. 2015;21:3131–9.
Oakes CC, La Salle S, Trasler JM, Robaire B. Restriction digestion and real-time PCR (qAMP). Methods Mol Biol. 2009;507:271–80.
Novak TJ, White PM, Rothenberg EV. Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res. 1990;18:4523–33.
Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, Varelias A, Alexander KA, Teal BE, Sparwasser T, et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood. 2012;119:5898–908.
Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol. 2012;189:464–74.
Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111:453–62.
Ballas ZK. The use of 5-azacytidine to establish constitutive interleukin 2-producing clones of the EL4 thymoma. J Immunol. 1984;133:7–9.
Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y, Wang Y, Ushijima T, Baba T, Shibuya K, et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J. 2006;25:1081–92.
Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol. 2003;4:235–40.
Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, Willems E, Gothot A, Vanbellinghen JF, Geenen V, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica. 2011;96:298–306.
Wu T, Young JS, Johnston H, Ni X, Deng R, Racine J, Wang M, Wang A, Todorov I, Wang J, Zeng D. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J Immunol. 2013;191:488–99.
Ehx G, Fransolet G, De Leval L, D’Hondt S, Lucas S, Hannon M, Delens L, Dubois S, Drion P, Beguin Y, et al. Azacytidine enhances regulatory T-cells in vivo and prevents experimental xenogeneic graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:s393–3.
Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol. 2016;9:39.
van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, Vellenga E, Huls G. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.
Steinmann J, Bertz H, Wasch R, Marks R, Zeiser R, Bogatyreva L, Finke J, Lubbert M. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant. 2015;50:690–5.
Craddock C, Jilani NY, Siddique S, Yap C, Khan JN, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2015.
Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119:3361–9.
Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socie G, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389–96.
Yu W, Nagaoka H, Jankovic M, Misulovin Z, Suh H, Rolink A, Melchers F, Meffre E, Nussenzweig MC. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization. Nature. 1999;400:682–7.
We are very grateful to Sandra Ormenese and Raafat Stephan from the Imaging and Flow Cytometry Platform of the GIGA, to the ImmunoHistology platform of the GIGA for histologic slides and the Genotranscriptomic platform of the GIGA for TCRVβ analyses. The authors are also grateful to Coline Daulne for excellent technical assistance.
This study was supported by funds from: the National Fund for Scientific Research (FNRS), the Leon Fredericq fund and Anti-Cancer Center at the University of Liège, and the Belgian Foundation Against Cancer. GF, GE, JM, and LD are Télévie Research Assistant, JS a Televie postdoctoral researcher, and FB is senior research associate of the National Fund for Scientific Research (FNRS) Belgium. SHB is a postdoctoral researcher from the Fonds Wetenschappelijk Onderzoek—Vlaanderen.
Availability of data and materials
The datasets supporting the conclusions of this article are included within this article and its additional files. Raw data are available on the GIGA extern mass storage and access can be provided upon request to the authors.
FB, GE, and SHB contributed to the design of the study. GF, GE, GC, and FB conducted the data analyses. JC and YB helped with the study design and data analyses. GF, GE, SD, LD, MH, and PD conducted mouse experiments. GF and GE conducted the flow cytometry analyses. JS, PD, and GF were in charge of histology. GC was in charge of PCR for methylation status of Foxp3 enhancer and IL-2 promoter. FB, GF, GE, and SHB were in charge of Ms writing. All authors read and approved the final manuscript.
FB has received travel grants from Celgene.
GF and GE are co-first authors; GC and FB are co-senior authors.
A): Azacytidine administered every fourth day failed to prevent cGVHD. (B) Decitabine administered every other day ameliorated cGVHD. Figure S2: Impact of Azacytidine on blood counts and immune recovery after syngeneic transplantation. Figure S3: Impact of decitabine on skin, lungs and immune recovery. Figure S4: Azacytidine enhances Treg frequency and functions after syngeneic transplantation. Figure S5: Azacytidine does not induce the generation of CD8+FoxP3+ regulatory T cells after allogeneic or syngeneic transplantation. Figure S6: Azacytidine does not restrict T-cell Vβ (TCR Vβ) repertoire diversity on day +35 and +52. (DOCX 10679 kb)
About this article
Cite this article
Fransolet, G., Ehx, G., Somja, J. et al. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. J Hematol Oncol 9, 53 (2016). https://doi.org/10.1186/s13045-016-0281-2
- Regulatory T cells
- Graft-versus-host disease
- Chronic graft-versus-host disease
- Sclerodermic graft-versus-host disease